Nektar's Rezpegaldesleukin Shows Promising Long-Term Efficacy in Atopic Dermatitis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy NKTR?
Source: NASDAQ.COM
- Durable Efficacy: Nektar Therapeutics reported that in the REZOLVE-AD Phase 2b study, 71% and 83% of patients maintained EASI-75 responses after 52 weeks of treatment with Rezpegaldesleukin, indicating its durable efficacy in moderate-to-severe atopic dermatitis patients.
- New Responses: During the 36-week maintenance phase, some patients achieved new or deeper responses, with EASI-100 response rates showing up to a five-fold increase, highlighting the drug's potential advantages in treatment outcomes.
- Favorable Safety Profile: Nektar noted that the safety profile of Rezpegaldesleukin remained consistent with earlier findings, with most adverse events being mild or moderate and low discontinuation rates across both dosing regimens, enhancing its clinical applicability.
- Future Development Plans: Nektar plans to advance Rezpegaldesleukin into Phase 3 studies with a goal of submitting a Biologics License Application (BLA) by 2029, demonstrating the company's confidence in the drug's market potential and therapeutic value.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NKTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NKTR
Wall Street analysts forecast NKTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NKTR is 103.71 USD with a low forecast of 30.00 USD and a high forecast of 135.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 37.070
Low
30.00
Averages
103.71
High
135.00
Current: 37.070
Low
30.00
Averages
103.71
High
135.00
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nektar to Host Investor Call on REZOLVE-AD Results
- Clinical Trial Update: Nektar Therapeutics will host an investor call on February 10, 2026, to review topline results from the 36-week maintenance period of the REZOLVE-AD clinical trial, which is expected to positively impact the company's positioning in the atopic dermatitis market.
- Product Candidate Overview: Nektar's lead candidate, rezpegaldesleukin, is a novel regulatory T-cell stimulator undergoing two Phase 2b trials for atopic dermatitis and alopecia areata, showcasing the company's innovative potential in immunotherapy.
- Diverse Clinical Trials: In addition to atopic dermatitis, Nektar is also conducting a Phase 2 trial for Type 1 diabetes, indicating the diversity of its pipeline and broad focus on chronic inflammatory diseases, which may lay the groundwork for future revenue growth.
- Live Webcast Availability: The investor call will be available via live webcast, with details accessible on Nektar's website, enhancing communication transparency with investors and potentially boosting market confidence.
See More
Nektar's Rezpegaldesleukin Shows Promising Long-Term Efficacy in Atopic Dermatitis
- Durable Efficacy: Nektar Therapeutics reported that in the REZOLVE-AD Phase 2b study, 71% and 83% of patients maintained EASI-75 responses after 52 weeks of treatment with Rezpegaldesleukin, indicating its durable efficacy in moderate-to-severe atopic dermatitis patients.
- New Responses: During the 36-week maintenance phase, some patients achieved new or deeper responses, with EASI-100 response rates showing up to a five-fold increase, highlighting the drug's potential advantages in treatment outcomes.
- Favorable Safety Profile: Nektar noted that the safety profile of Rezpegaldesleukin remained consistent with earlier findings, with most adverse events being mild or moderate and low discontinuation rates across both dosing regimens, enhancing its clinical applicability.
- Future Development Plans: Nektar plans to advance Rezpegaldesleukin into Phase 3 studies with a goal of submitting a Biologics License Application (BLA) by 2029, demonstrating the company's confidence in the drug's market potential and therapeutic value.
See More
Nektar Launches Pivotal Late-Stage Program for Atopic Dermatitis
- Clinical Trial Success: Nektar Therapeutics announced positive mid-stage trial results for its atopic dermatitis candidate rezpegaldesleukin, with 71% and 83% of patients maintaining the EASI-75 clinical measure after a 16-week induction period, indicating strong efficacy and market potential.
- Significant Dose Effects: The percentage of patients achieving EASI-100 increased 2- to 5-fold with 24 µg/kg monthly and quarterly dosing, demonstrating the drug's substantial effectiveness in treating moderate to severe atopic dermatitis, which may attract increased investor interest.
- Good Safety Profile: The company reported no new safety signals during the trial, with a discontinuation rate due to adverse events at only 3.5%, further bolstering market confidence in the drug and potentially accelerating the progression to later clinical stages.
- Clear Future Plans: Nektar plans to quickly initiate a Phase 3 trial for rezpegaldesleukin and expects to file for a marketing application by 2029, reflecting the company's strong confidence in the drug and proactive response to market demand.
See More
Nektar Therapeutics Shares Surge 14% on Positive Trial Results
- Clinical Trial Success: Nektar Therapeutics reported positive results from the 36-week blinded maintenance period of its 52-week REZOLVE-AD study for the experimental drug rezpegaldesleukin, significantly enhancing the company's competitive position in the dermatology market.
- Stock Price Surge: Following the announcement, Nektar's shares rose over 14% in Tuesday's pre-market trading, reflecting optimistic investor sentiment regarding the company's future prospects, which may attract more capital inflow.
- High Market Sentiment: Retail sentiment around Nektar trended in the 'extremely bullish' territory at the time of writing, with message volumes at 'extremely high' levels, indicating strong investor confidence in its growth potential, which could drive further stock price increases.
- Social Media Buzz: NKTR stock was among the top ten trending tickers on the platform, demonstrating heightened market attention to its clinical advancements, potentially increasing its visibility and attractiveness among investors.
See More
Nektar Therapeutics Reports Positive Results for Rezpegaldesleukin in Atopic Dermatitis Study
- Significant Efficacy Improvement: In the 52-week REZOLVE-AD study, 71% and 83% of patients maintained EASI-75 responses with monthly and quarterly dosing of 24 µg/kg, indicating substantial efficacy and potential in treating atopic dermatitis.
- Favorable Safety Profile: The safety of rezpegaldesleukin was consistent with prior results, with a 72% incidence of treatment-emergent adverse events during the 36-week maintenance period, and most injection site reactions were mild, demonstrating good tolerability.
- Durability of Response: The maintenance treatment showed up to a 5-fold increase in EASI-100 response rates, supporting the advancement to pivotal Phase 3 trials to further validate its potential as an immune modulator.
- Broad Market Potential: Nektar plans to submit a Biologics License Application (BLA) by 2029, reflecting confidence in the market opportunity for rezpegaldesleukin in atopic dermatitis treatment, potentially making it a first-in-class therapy.
See More
Nektar Announces Positive Results for Rezpegaldesleukin in Atopic Dermatitis Study
- Significant Efficacy Improvement: In the 52-week REZOLVE-AD study, 71% and 83% of patients maintained EASI-75 responses with monthly and quarterly dosing of 24 µg/kg, indicating substantial efficacy and the drug's potential in treating atopic dermatitis.
- Favorable Safety Profile: Rezpegaldesleukin demonstrated a safety profile consistent with previous results, with a 72% adverse event rate during the 36-week maintenance period, predominantly mild reactions, showcasing the drug's good tolerability.
- Long-Term Effectiveness Validated: The 24 µg/kg monthly and quarterly dosing regimens resulted in EASI-100 response rates increasing to 22% and 18% during maintenance, indicating effective disease control over prolonged treatment, which holds significant clinical implications.
- Strategic Advancement: Nektar plans to initiate Phase 3 clinical trials promptly, aiming for a Biologics License Application submission by 2029, thereby reinforcing its market position in the treatment of atopic dermatitis.
See More
Nektar to Host Investor Call on REZOLVE-AD Results
- Clinical Trial Update: Nektar Therapeutics will host an investor call on February 10, 2026, to review topline results from the 36-week maintenance period of the REZOLVE-AD clinical trial, which is expected to positively impact the company's positioning in the atopic dermatitis market.
- Product Candidate Overview: Nektar's lead candidate, rezpegaldesleukin, is a novel regulatory T-cell stimulator undergoing two Phase 2b trials for atopic dermatitis and alopecia areata, showcasing the company's innovative potential in immunotherapy.
- Diverse Clinical Trials: In addition to atopic dermatitis, Nektar is also conducting a Phase 2 trial for Type 1 diabetes, indicating the diversity of its pipeline and broad focus on chronic inflammatory diseases, which may lay the groundwork for future revenue growth.
- Live Webcast Availability: The investor call will be available via live webcast, with details accessible on Nektar's website, enhancing communication transparency with investors and potentially boosting market confidence.
See More
Nektar's Rezpegaldesleukin Shows Promising Long-Term Efficacy in Atopic Dermatitis
- Durable Efficacy: Nektar Therapeutics reported that in the REZOLVE-AD Phase 2b study, 71% and 83% of patients maintained EASI-75 responses after 52 weeks of treatment with Rezpegaldesleukin, indicating its durable efficacy in moderate-to-severe atopic dermatitis patients.
- New Responses: During the 36-week maintenance phase, some patients achieved new or deeper responses, with EASI-100 response rates showing up to a five-fold increase, highlighting the drug's potential advantages in treatment outcomes.
- Favorable Safety Profile: Nektar noted that the safety profile of Rezpegaldesleukin remained consistent with earlier findings, with most adverse events being mild or moderate and low discontinuation rates across both dosing regimens, enhancing its clinical applicability.
- Future Development Plans: Nektar plans to advance Rezpegaldesleukin into Phase 3 studies with a goal of submitting a Biologics License Application (BLA) by 2029, demonstrating the company's confidence in the drug's market potential and therapeutic value.
See More
Nektar Launches Pivotal Late-Stage Program for Atopic Dermatitis
- Clinical Trial Success: Nektar Therapeutics announced positive mid-stage trial results for its atopic dermatitis candidate rezpegaldesleukin, with 71% and 83% of patients maintaining the EASI-75 clinical measure after a 16-week induction period, indicating strong efficacy and market potential.
- Significant Dose Effects: The percentage of patients achieving EASI-100 increased 2- to 5-fold with 24 µg/kg monthly and quarterly dosing, demonstrating the drug's substantial effectiveness in treating moderate to severe atopic dermatitis, which may attract increased investor interest.
- Good Safety Profile: The company reported no new safety signals during the trial, with a discontinuation rate due to adverse events at only 3.5%, further bolstering market confidence in the drug and potentially accelerating the progression to later clinical stages.
- Clear Future Plans: Nektar plans to quickly initiate a Phase 3 trial for rezpegaldesleukin and expects to file for a marketing application by 2029, reflecting the company's strong confidence in the drug and proactive response to market demand.
See More
Nektar Therapeutics Shares Surge 14% on Positive Trial Results
- Clinical Trial Success: Nektar Therapeutics reported positive results from the 36-week blinded maintenance period of its 52-week REZOLVE-AD study for the experimental drug rezpegaldesleukin, significantly enhancing the company's competitive position in the dermatology market.
- Stock Price Surge: Following the announcement, Nektar's shares rose over 14% in Tuesday's pre-market trading, reflecting optimistic investor sentiment regarding the company's future prospects, which may attract more capital inflow.
- High Market Sentiment: Retail sentiment around Nektar trended in the 'extremely bullish' territory at the time of writing, with message volumes at 'extremely high' levels, indicating strong investor confidence in its growth potential, which could drive further stock price increases.
- Social Media Buzz: NKTR stock was among the top ten trending tickers on the platform, demonstrating heightened market attention to its clinical advancements, potentially increasing its visibility and attractiveness among investors.
See More
Nektar Therapeutics Reports Positive Results for Rezpegaldesleukin in Atopic Dermatitis Study
- Significant Efficacy Improvement: In the 52-week REZOLVE-AD study, 71% and 83% of patients maintained EASI-75 responses with monthly and quarterly dosing of 24 µg/kg, indicating substantial efficacy and potential in treating atopic dermatitis.
- Favorable Safety Profile: The safety of rezpegaldesleukin was consistent with prior results, with a 72% incidence of treatment-emergent adverse events during the 36-week maintenance period, and most injection site reactions were mild, demonstrating good tolerability.
- Durability of Response: The maintenance treatment showed up to a 5-fold increase in EASI-100 response rates, supporting the advancement to pivotal Phase 3 trials to further validate its potential as an immune modulator.
- Broad Market Potential: Nektar plans to submit a Biologics License Application (BLA) by 2029, reflecting confidence in the market opportunity for rezpegaldesleukin in atopic dermatitis treatment, potentially making it a first-in-class therapy.
See More
Nektar Announces Positive Results for Rezpegaldesleukin in Atopic Dermatitis Study
- Significant Efficacy Improvement: In the 52-week REZOLVE-AD study, 71% and 83% of patients maintained EASI-75 responses with monthly and quarterly dosing of 24 µg/kg, indicating substantial efficacy and the drug's potential in treating atopic dermatitis.
- Favorable Safety Profile: Rezpegaldesleukin demonstrated a safety profile consistent with previous results, with a 72% adverse event rate during the 36-week maintenance period, predominantly mild reactions, showcasing the drug's good tolerability.
- Long-Term Effectiveness Validated: The 24 µg/kg monthly and quarterly dosing regimens resulted in EASI-100 response rates increasing to 22% and 18% during maintenance, indicating effective disease control over prolonged treatment, which holds significant clinical implications.
- Strategic Advancement: Nektar plans to initiate Phase 3 clinical trials promptly, aiming for a Biologics License Application submission by 2029, thereby reinforcing its market position in the treatment of atopic dermatitis.
See More
